News AZ grabs licence as Ionis NASH drug heads to the clinic Could antisense drug be a fatty liver disease blockbuster?
News Regeneron and Alnylam seek RNAi therapies for NASH Regeneron and Alnylam are to research treatments for the chronic liver disease non-alcoholic steatohepatitis (NASH), under a new agreement.
News Sanofi passes on Alnylam's breakthrough therapy Alnylam is to forge ahead with a rare disease therapy on its own after Sanofi decided to opt out of a co-development and co-marketing deal.
News AZ signs kidney drug deal with Ionis for up to $330m Deal is result of six-year collaboration with AZ
News Alnylam beats Ionis in RNA drug battle Alnylam and Sanofi have revealed full phase 3 data on their RNA interference (RNAi) drug patisiran, soundly beating a rival candidate from Ionis, inotersen.
News Alnylam soars after drug success, paving way for RNAi era Shares in US biotech Alnylam have soared after a late-stage study of its RNA interference drug patisaran met its primary endpoint.
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
